Margaretha Stam Moraga

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Nicola De Stefano, Mark S. Freedman, Frederik Barkhof et al. · The Lancet Neurology · 2011 · 212 citations

Neurological Disorder, Clinical Neurology, Neurology +5

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy

Magnhild Sandberg‐Wollheim, Enrica Alteri, Margaretha Stam Moraga et al. · Multiple Sclerosis Journal · 2011 · 123 citations · Full text

Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-??-1a

Gordon Francis, Yves Grumser, Enrica Alteri et al. · Drug Safety · 2003 · 96 citations

Hepatology, Medicine, Liver Physiology +9

Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis

Sílvia Tenembaum, Brenda Banwell, Daniela Pohl et al. · Journal of Child Neurology · 2013 · 83 citations · Full text

Neurological Disorder, Immunodeficiencies, Immunology +17

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings

Magnhild Sandberg‐Wollheim, Gabrielle Kornmann, Dorina Bischof et al. · Multiple Sclerosis Journal · 2011 · 31 citations · Full text